Filed January 27, 2025

On behalf of **AZURITY PHARMACEUTICALS INC.**
By: Andrew Morrell, Ajay Kayal, Leah Digby
WINDELS MARX LANE & MITTENDORF, LLP
One Giralda Farms
Madison, NJ 07940
Tel.: 973-966-3200 Fax: 976-966-3250
Email: AzurityIPRs@windelsmarx.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AZURITY PHARMACEUTICALS INC.
Petitioner,

v.

EXELIXIS, INC.
Patent Owner.

IPR2025-00210
Patent 11,298,349

AZURITY SUPPLEMENTAL MANDATORY NOTICES: RELATED MATTERS

Pursuant to 37 C.F.R. §§ 42.8(a)(3) and (b)(2), Petitioner Azurity Pharmaceuticals, Inc. ("Azurity") provides the following supplemental information regarding related matters.

Additional Related Matters

Azurity provides the following supplemental information regarding related matters to include the assigned AIA Review Number for a new petition for *inter partes* review. Azurity filed this petition for *inter partes* review on January 9, 2025 against Exelixis, Inc., owners of the challenged patent:

- IPR2025-00427, U.S. Pat. 12,128,039

Respectfully submitted,

Dated: January 27, 2025 By: /Andrew E. Morrell/

Andrew E. Morrell (Reg. No. 63,737)
Ajay Kayal (Reg. No. 66,691)
Leah Digby (Reg. No. 82,956)

WINDELS MARX LANE & MITTENDORF, LLP
Email: AzurityIPRs@windelsmarx.com

Attorneys/Practitioners for Petitioner
Azurity Pharmaceuticals, Inc.

CERTIFICATE OF SERVICE

I hereby certify that a true and correct copy of the foregoing **AZURITY SUPPLEMENTAL MANDATORY NOTICES: RELATED MATTERS** is being served on January 27, 2025, via email pursuant to agreement of the parties to:

Emily R. Whelan
Emily.Whelan@wilmerhale.com
Cindy Kan
Cindy.Kan@wilmerhale.com
WH_Exelixis_IPR@wilmerhale.com
WILMER CUTLER PICKERING HALE AND DORR LLP
60 State Street
Boston, MA 02109

Dated: January 27, 2025 By: /Andrew E. Morrell/

Andrew E. Morrell (Reg. No. 63,737)
Ajay Kayal (Reg. No. 66,691)
Leah Digby (Reg. No. 82,956)

WINDELS MARX LANE & MITTENDORF, LLP
Email: AzurityIPRs@windelsmarx.com

Attorneys/Practitioners for Petitioner
Azurity Pharmaceuticals, Inc.